Search
2025
2024
2023
-
Apr 10, 2025
YOLT-202 Receives FDA Orphan Drug DesignationRead More
-
Mar 26, 2025
YolTech Therapeutics Announces Favorable Interim Results from Ongoing IIT that Single-Dose Administration of YOLT-101, an In Vivo Gene Editing Therapy, Effectively Reduces LDL-C in Familial HypercholesterolemiaRead More
-
Mar 21, 2025
YolTech Therapeutics Announces GMP Manufacturing Facility Expansion to Support Gene Editing Therapy Commercial ManufacturingRead More
-
Mar 11, 2025
YolTech Therapeutics Announces Positive Clinical Results for YOLT-201, an Investigational In Vivo Gene Editing Therapy for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Read More
-
Feb 25, 2025
YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)Read More
